Abstract
BackgroundJanus Kinase (JAK) inhibitors, including upadacitinib, are approved for clinical use, and show good therapeutic responses in Rheumatoid arthritis (RA) patients. In addition to impacts on cytokine signaling in immune...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
